BIOVF - Swedish Orphan Biovitrum: A Rare Disease Company Undervalued By 20%
Swedish Orphan Biovitrum (STO:SOBI) (OTC:BIOVF) is a USD 6.2B Swedish biopharmaceutical company engaged in the research, production and distribution of treatments dedicated to rare diseases. In this article, I will provide an in-depth analysis of this company.
NB: SOBI has its primary listing on Nasdaq OMX Stockholm. Shares as well as financial results are SEK denominated, so all financial and share data will be presented in SEK. Interim results are provided on a three-months basis. The Group prepares its results in accordance with IFRS accounting standards. We will use SEK 214.0 as the